Danaher Co. (NYSE:DHR) Shares Purchased by Fiduciary Alliance LLC

Fiduciary Alliance LLC increased its holdings in Danaher Co. (NYSE:DHR) by 0.4% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 27,276 shares of the conglomerate’s stock after acquiring an additional 114 shares during the period. Danaher makes up about 1.2% of Fiduciary Alliance LLC’s holdings, making the stock its 26th largest holding. Fiduciary Alliance LLC’s holdings in Danaher were worth $6,759,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Avalon Capital Management acquired a new position in Danaher during the first quarter worth $271,000. Cornerstone Wealth Group LLC acquired a new stake in Danaher during the first quarter valued at approximately $261,000. Annapolis Financial Services LLC lifted its position in Danaher by 58.9% in the 1st quarter. Annapolis Financial Services LLC now owns 232 shares of the conglomerate’s stock valued at $58,000 after purchasing an additional 86 shares during the last quarter. River Street Advisors LLC lifted its position in Danaher by 19.6% in the first quarter. River Street Advisors LLC now owns 2,045 shares of the conglomerate’s stock worth $511,000 after purchasing an additional 335 shares during the period. Finally, New Mexico Educational Retirement Board grew its position in Danaher by 7.2% in the first quarter. New Mexico Educational Retirement Board now owns 37,035 shares of the conglomerate’s stock worth $9,248,000 after buying an additional 2,500 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

DHR has been the topic of several research reports. TD Cowen upped their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and lifted their target price for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Robert W. Baird boosted their price target on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Finally, Barclays increased their target price on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 24th. Six equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $269.29.

Insider Activity at Danaher

In other Danaher news, CEO Rainer Blair sold 9,005 shares of the company’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the sale, the chief executive officer now directly owns 106,990 shares in the company, valued at $28,352,350. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Rainer Blair sold 9,005 shares of Danaher stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the sale, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at $28,352,350. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Matthew Mcgrew sold 46,377 shares of Danaher stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $253.05, for a total value of $11,735,699.85. Following the completion of the transaction, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $7,441,441.35. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 148,783 shares of company stock valued at $37,536,717. 11.10% of the stock is owned by corporate insiders.

Danaher Trading Down 0.7 %

DHR stock traded down $1.64 during midday trading on Friday, hitting $249.85. 4,638,276 shares of the company’s stock were exchanged, compared to its average volume of 3,371,169. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The business has a 50-day simple moving average of $255.96 and a two-hundred day simple moving average of $246.61. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $269.11. The stock has a market capitalization of $185.06 billion, a PE ratio of 42.35, a P/E/G ratio of 3.82 and a beta of 0.85.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same quarter last year, the company earned $2.36 earnings per share. On average, sell-side analysts predict that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 annualized dividend and a yield of 0.43%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.